Company
Kairos Pharma, LTD. (KAPA)
Standardized SEC financial data for Kairos Pharma, LTD. — income statement, balance sheet, cash flow and 40+ ratios, as a clean JSON API. CIK 0001962011 · NYSE · Pharmaceutical Preparations.
Return on equity
-85.9%
Free cash flow
-$3.4M
Current ratio
27.07×
EPS (diluted)
$-0.30
Income statement
| USD | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| R&D expense | $82K | $414K | $2.1M |
| SG&A expense | $1.6M | $1.9M | $3.4M |
| Operating income | -$1.7M |
Balance sheet
| USD | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Cash & equivalents | $437K | $93K | $1.3M | $4.5M |
| Total current assets | — | $101K | $4.2M | $5.4M |
Cash flow
| USD | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating cash flow | $81K | -$4.0M | -$3.4M |
| Financing cash flow | -$425K | $5.1M | $6.7M |
| Dividends paid | $0 | $0 |
Get KAPA data via API
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/KAPA/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/KAPA/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"